UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2001 Shire Pharmaceuticals Group plc - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) England and Wales - -------------------------------------------------------------------------------- (State or other jurisdiction of incorporation) 0-29630 N/A - --------------------------- ----------------------------------- (Commission File Number) (IRS Employer Identification No.) East Anton, Andover, Hampshire SP10 5RG England - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code 44-1264-333455 ------------------------------ - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) -2- Item 7. Financial Statements and Exhibits (c) Exhibits: 99.1 Pro Forma Financial Data -3- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 15, 2001 SHIRE PHARMACEUTICALS GROUP PLC By: /s/ ANGUS RUSSELL ----------------------------------------- Name: Angus Russell Title: Group Finance Director -4- EXHIBIT INDEX Exhibit Number Description 99.1 Pro Forma Financial Data